Silva et al.33
|
Brazil, 2020 |
To evaluate the associations between the IFNL3 gene (rs12979860) and the clinical outcomes in children with dengue. |
DF: 96 DHF/DFC: 110 |
WHO, 1997 |
qRT-PCR using TaqMan |
A1 |
Innate immunity (interferon lambda 3) |
rs12979860 |
Inconclusive: rs12979860. Risk: allele T of IFNL3 gene |
Santos et al.34
|
Brazil, 2019 |
To assess whether SNPs in serotonin and nitric oxide were associated with the risk of progression of dengue hemorrhagic fever in a sample of Brazilian patients. |
DF: 78 DHF: 49 |
WHO, 1997 |
qRT-PCR using TaqMan |
A3 |
Innate immunity (nitric oxide and serotonin) |
rs1799983 |
Protective: rs1799983, rs2430561 y rs25531 |
Falcón et al.45
|
Mexico, 2009 |
To analyze possible associations between HLA class I and II polymorphisms and the severity of the clinical disease caused by dengue virus infection in mestizo Mexican patients. |
DF: 23 DHF: 16 Controls: 34 |
WHO, 2008 |
PCR-SSO and nucleotide sequencing method for subtype identification |
B |
Genetic |
HLA |
Risk: HLA-B and HLA-DQB1 |
Figueiredo et al.35
|
Brazil, 2016 |
To evaluate the influence of MBL2 polymorphisms as a modifier condition of dengue progression |
DF: 104 DHF:57 |
WHO, 1997 |
qRT-PCR using TaqMan |
A2 |
Innate immunity (MBL2) |
MBL2 polymorphisms |
Risk: OO genotype and O allele (low production of MBL2) |
García et al.52
|
Cuba, 2010 |
To investigate the role of the FcγRIIa polymorphism in a group of Cuban individuals with a history of DH, FD, or asymptomatic dengue. |
DF:68 DHF/DSS:29 Subclinical: 42 |
WHO, 1997 |
PCR-SSO |
B |
Genetic |
FcγRIIa polymorphisms |
Protective: genotype RR131 Risk: genotype HH131 |
Noecker et al.46
|
Mexico, 2014 |
To characterize the frequency and distribution of the FcγRIIa and DC-SIGN polymorphisms and to compare their distribution among asymptomatic, uncomplicated, and severe dengue cases in Morelos, Mexico. |
Asymptomatic: 145 uncomplicated: 67 Severe dengue:36 |
WHO, 2009 |
qRT-PCR using TaqMan |
A3 |
Innate immunity (histidine) |
rs1801274, rs4804803 |
Protective: rs1801274 Risk: rs4804803 |
Ornelas et al.36
|
Brazil, 2019 |
To investigate the association between the MBL2, CLEC5A, ITGB3 and CCR5 genes and the severity of dengue in children |
Dengue severe cases: 87 Controls:197 |
Brazilian Ministry of Health. WHO, 2009 |
qRT-PCR using QuantStudio |
A2 |
Innate immunity (MBL2) |
rs7095891, rs1800450, rs1800451, rs4935047, rs930509, rs2120131 and rs2099902 |
Risk: rs7095891G, rs1800450C, rs1800451C, rs4935047A, rs930509G, rs2120131G, rs2099902C, rs4935047G and rs7095891G |
Pastor et al.37
|
Brazil, 2013 |
To determine the relationship between allele/haplotype variants of the CFH gene and the clinical outcome in patients with DENV-3 dengue infection |
DF:34 DHF:87 Healthy: 93 |
WHO, 2004 |
PCR amplification reaction using GeneAmp Genotyping the C-257T PCR using TaqMan |
A3 |
Innate immunity (complement factor H) |
rs800292, exon 14 rs3753396 exon 19 and rs1065489 |
Protective: rs3753394 and rs800292 |
Santos et al.38
|
Brazil, 2017 |
To evaluate the influence of IL-10, TNFA and IFNG gene polymorphisms on the susceptibility to dengue infection or progression in a sample of Brazilian patients |
DF: 78 DHF: 49 Healthy controls: 135 |
WHO, 1997 |
qRT-PCR using TaqMan; and amplification refractory mutation system-PCR |
A1 |
Innate immunity (TNFA, IL10 e INFG) |
rs3753394 (C-257T), rs800292 (G257A), rs3753396 (A2089G) and rs1065489 (G2881T) |
Protective: rs2430561 Risk: rs180871 |
Vargas-Castillo et al.47
|
Mexico, 2018 |
To identify the association between seven gene polymorphisms related to the immune response and severe presentations of dengue infection in patients from an endemic region of Mexico |
DF: 138 DHF: 31 Healthy controls: 304 |
WHO, 1997 |
qRT-PCR using TaqMan |
A1 |
Innate immunity (TNF) |
rs1800629 (TNF), rs4804803 (CD209), rs2780831 (JAK1), rs1801274 (FCGR2A), rs231775 (CTLA4), rs12979860, and rs8099917 |
Risk: rs1800629 |
Xavier-Carvalho et al.39
|
Brazil, 2013 |
To evaluate the impact of TNF, IL-10, MIF, DC-SIGN, CLEC5A, NOD2, CCR5 and MRC1 polymorphisms on patients’ susceptibility to dengue infection and on the progression of this disease |
SD: 88 Healthy controls: 335 |
WHO, 2009 |
qRT-PCR using TaqMan |
A1 |
Innate immunity (TNF, CLEC5A) |
rs1800629, rs1800871, rs4804803, rs755622 rs333, rs1926736 rs2066843 and rs751271 |
Protective: rs4804803 Risk: rs1285933 |
Xavier-Carvalho et al.40
|
Brazil, 2017 |
To determine the association between the CLEC5A polymorphism and severe dengue infection in a Brazilian population, in order to investigate the functional effect of CLEC5A in an in vitro experiment with blood samples from patients infected with dengue |
SD: 151 Mild dengue: 62 |
WHO, 2009 |
qRT-PCR using TaqMan |
A3 |
Innate immunity (CLEC5A) |
rs1285933 |
Risk: rs1285933 |
Azevedo et al.41
|
Brazil, 2019 |
To verify the relationship between the single nucleotide polymorphism (SNP) of the G2431A IDO1 gene (rs3739319) and the development of severe dengue. |
395 DWOS:131 DWS:143 SD:25 Healthy: 96 |
WHO, 2009 |
qRT-PCR using TaqMan |
B |
Genetic (AA IDO1) |
rs3739319 |
Protective: rs3739319GG Risk: rs3739319AA |
Oliveira et al.42
|
Brazil, 2014 |
To determine the possible association between the rs4804803 polymorphism and the dengue virus and its pathogenesis. |
FD: 156 DHF: 12 Controls: 72 |
Brazilian Ministry of Health. WHO, 2009 |
qRT-PCR using TaqMan |
B |
Genetic |
rs4804803 |
Protective: rs4804803GG |
Silva et al.43
|
Brazil, 2010 |
To identify the genes associated with the clinical presentation of dengue. |
DHF: 50 FD:236 Asymptomatic :236 |
Brazilian Ministry of Health. WHO, 1997 |
BeadArray technology |
A1 |
Innate immunity (INF1) |
rs11208534, rs2780831 and rs310196 |
Protective: rs11208534, rs2780831 and rs310196 |
Fernández-Mestre et al.56
|
Venezuela, 2009 |
To analyze the frequency of HLA class I (-A, -B and -C) and class II (-DRB1) polymorphisms in Venezuelan patients with FD and DHF and the relationship between these polymorphisms and the clinical manifestations of the disease. |
DF: 43 DHF: 28 Not clinically classified:6 Healthy controls:127 |
WHO, 1997 |
PCR-SSO reverse using the Dynal RELI |
B |
Genetic |
B*15, B*49, DRB1*02 and DRB1*03 |
Protective: A*03 Risk: B*57 and B*40 |
Posadas-Mondragón et al.48
|
Mexico, 2020 |
To explore the association between SNPs in TLRs and the clinical forms of dengue in the Mexican adult population |
DF:100 DHF:65 Healthy adults:89 |
WHO, 1997 |
qRT-PCR using Applied Biosystems genotyping assays. |
A3 |
Innate immunity (Receptor Toll) |
rs3775291, rs4986791, rs4986790, rs3764880, rs6552950, rs2737190, rs11536865, rs179008, rs3853839, rs5741883, rs1548731 and rs10983755 |
Protective: TLR4-rs2737190-G/G and TLR4-rs11536865-G/C |
Sánchez-Leyva et al.49
|
Mexico, 2017 |
To evaluate the relationship between the polymorphisms of genes -308 and -238 of the tumor necrosis factor alpha (TNF-α) and its circulating serum levels, and patients’ susceptibility to dengue virus infection and its different clinical and laboratory manifestations in an endemic region of Mexico. |
DF: 182 DHF: 69 Controls: 275 |
WHO, 1997 |
PCR - RFLP |
A1 |
Innate immunity (TNF-α) |
TNF-308 and TNF-238 |
Protective: -308G/A |
García et al.53
|
Cuba, 2011 |
To analyze the polymorphisms of the non-classical HLA class I MICA-MICB genes in Cuban adults infected with DV-4 during the 2006 epidemic. |
DF:68 DHF:36 Asymptomatic:42 Control population:155 |
WHO, 1997 |
PCR amplification using Taq |
B |
Genetic |
MICA and MICB |
Risk: MICA*008 and MICB*008 |
García-Trejo et al.50
|
Mexico, 2011 |
To evaluate the relationship between polymorphisms of the TNF-α gene and genetic susceptibility to dengue in a group of mestizo patients from the State of Morelos, Mexico. |
DF:85 DHF:45 Healthy controls:169 |
WHO, 1997 |
PCR - RFLP |
A1 |
Innate immunity (TNF-α) |
TNF-308 and TNF-238 |
Protective: TNFA - 238A |
Sierra et al.54
|
Cuba, 2007 |
To examine the HLA-A/B class I and HLA-DRB1 class II polymorphisms in Cuban individuals with a history of DF or DHF during primary and secondary dengue 2 infections during the 1997 outbreak. |
DF:73 DHF:47 Healthy controls: 189 |
WHO, 1994 |
PCR-SSP |
B |
Genetic |
HLA-A/B class I, and HLA-DRB1 class II |
Protective: HLA-DRB1 Risk: HLA-I |
Pérez et al.55
|
Cuba, 2010 |
To analyze the polymorphisms of cytokine genes in a group of individuals who developed DHF during the 1997 epidemic. |
DHF: 43 Healthy controls: 99 |
WHO, 1997 |
PCR-SSP |
A1 |
Innate immunity (TNF-α) |
TNF (308 A/G), IFN (874A/T), TGF-1 (codon 10 T/C and codon 25 G/C), IL-10 (1082 A/G, 819 C/T, 592 A/C), IL-6, 174 G C) |
Risk: TNF- (308) GG and TGF-1 (c25) GG |
Sierra et al.19
|
Cuba, 2017 |
To demonstrate whether the expression of OSBPL10 protects individuals against dengue infection in a Cuban population of African descent. |
Habana: DF:36 DHF:31 Asymptomatic: 32 Healthy: 47 Guantanamo: DF:41 DHF:29 healthy: 42 Asymptomatic: 16 |
WHO, 1997 |
qRT-PCR using LightCycler RNA |
B |
Genetic |
RXRA y OSBPL10 |
Protective: LXR/RXR |
Santos et al.44
|
Brazil, 2020 |
To identify the effect of the SNPs TNF-α-308G/A and -238G/A on a population from north-eastern Brazil. |
DF:108 DHF:50 Controls: 123 |
Not reported |
qRT-PCR using TaqMan; and Fast-Time PCR Thermocycler |
A1 |
Innate immunity (TNF-α) |
TNF -308G/A and -238G/A |
Protective: SNP-308G/A and SNP238A/A Risk: SNP-308G/G and SNP238G/A |
LaFleur et al.51
|
Mexico, 2002 |
To determine the association between HLA-DRB1 alleles and dengue hemorrhagic fever in Mexico. |
DHF:34 DF:47 |
WHO, 1997 |
PCR-SSO reverse |
B |
Genetic |
HLA-DRB1 HLA-DR4 |
Protective: HLA-DR4 |
Fernadez-Mestre et al.57
|
Venezuela, 2004 |
To analyze selected single-nucleotide polymorphisms (SNPs) of several cytokine genes [(TNF)-a, (IFN)-g, (IL)-6, (TGF)-b1 and IL-10)] in patients with dengue virus infections and to assess their relationship with patients’ susceptibility to dengue virus disease. |
DHF:25 DF:41 |
Not reported |
PCR-SSP |
A1 |
Innate immunity (TNF-α) |
TNF-308A, INFG, IL10 e IL6 |
Risk: TNF-308A |